Apollo Hospitals to acquire IFC's 31% stake in Apollo Health for ₹1,254 crore

Healthcare major Apollo Hospitals Enterprise Limited (AHEL) on Friday, September 12, announced that its wholly-owned subsidiary, Apollo Health and Lifestyle Limited (AHLL), will be fully consolidated by acquiring the 31% stake held by the Finance Corporation (IFC) for ₹1,254 crore.

Upon completion, Apollo Health and Lifestyle Limited will become a 99.42% subsidiary of Apollo, with the remaining 0.58% held under the employee stock option plan (ESOP). The transaction, expected to close by November 2025, is subject to approval from the Competition Commission of India.

This acquisition aims to strengthen Apollo’s integrated healthcare platform and enable sharper capital allocation, disciplined growth, and operational synergy across its business segments.

Also Read: Apollo Hospitals promoter Suneeta Reddy likely to offload partial stake via block deal: Sources

Apollo Health and Lifestyle, engaged in providing primary care, diagnostics, birthing and women's health, ambulatory care, dialysis, and dental services, recorded a consolidated turnover of ₹1,553.5 crore in FY25.

Doubling oncology business to over ₹5,000 crore in 4 years

In addition, the board approved an investment of ₹5,730 million to set up a comprehensive oncology centre at Gurugram. The facility will include the next-generation single gantry Proteus One Proton Beam Therapy system and aims to add capacity for an additional 350 patients annually.

The centre is part of Apollo’s phase 2 expansion at Gurugram, following the first phase, with the oncology centre expected to be operational within four years.

Also Read: Apollo Hospitals shares gain 4% after value unlocking exercise with NewCo

Apollo’s oncology expansion is designed to address India’s growing cancer burden. The initiative includes five key treatment areas — next-generation proton therapy, advanced robotics for surgery, high-end linear accelerators, immunotherapy and targeted therapies, and genomics-driven medicine. The plan also encompasses bone marrow transplants and CAR T-cell therapies to treat blood disorders and complex malignancies.

With this acquisition and investment, Apollo aims to double its oncology business to over ₹5,000 crore within 3-4 years, focusing on personalised care, precision medicine, and expansion into major cities. The Gurugram centre will be the third proton therapy facility in India, reinforcing Apollo’s leadership in advanced cancer care.

Shares of Apollo Hospitals Enterprise Ltd ended at ₹7,873.25, down by ₹5.75 or 0.073%, on the BSE today, September 12.

Also Read: Apollo Hospitals to add four new facilities, 500 beds by FY26 end